Mode of Administration: subcutaneously

2 trials

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: M808- Other osteoporosis with current pathological fracture

Phase 3

A study of Goserelin 3.6 mg Injection in patients with Breast cancer.

Active, not recruitingCTRI/2020/02/023101

Eurofarma Laboratorios SAHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site

Target: 68Updated: 2023-03-06

Phase 4

A study of Denosumab in postmenopausal women and men with osteoporosis (weak and brittle bones) at high risk of fracture

Active, not recruitingCTRI/2018/10/016049

Intas Pharmaceuticals Ltd Biopharma DivisionHealth Condition 1: M808- Other osteoporosis with current pathological fracture

Target: 200Updated: 2021-11-24

Mode of Administration: subcutaneously

Sponsors

Conditions

Phase 3

Phase 4